Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Rochester, MN
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Jackson, MS
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Jackson, MS
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Jefferson City, MO
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Jefferson City, MO
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Omaha, NE
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Las Vegas, NV
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lebanon, NH
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lebanon, NH
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lake Success, NY
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lake Success, NY
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New York, NY
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New York, NY
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New York, NY
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Stony Brook, NY
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Charlotte, NC
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Winston-Salem, NC
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fargo, ND
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fargo, ND
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Cincinnati, OH
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Cleveland, OH
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Toledo, OH
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Toledo, OH
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Portland, OR
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Providence, RI
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Providence, RI
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Charleston, SC
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Sumter, SC
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Sumter, SC
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Memphis, TN
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Temple, TX
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Temple, TX
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Portsmouth, VA
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Portsmouth, VA
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Richmond, VA
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Seattle, WA
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
15
mi
from
Concord,
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
15
mi
from
Concord,
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Washington,
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bronx, NY
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
Urine Proteome of Surgical Patients and Healthy Volunteers
Urine Proteome of Surgical Patients and Healthy Volunteers.
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Urine Proteome of Surgical Patients and Healthy Volunteers
Urine Proteome of Surgical Patients and Healthy Volunteers.
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
St. Joseph's Orange
mi
from
Orange, CA
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
St. Joseph's Orange
mi
from
Orange, CA
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
Penrose Cancer Center
mi
from
Colorado Springs, CO
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
Penrose Cancer Center
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
The Hartford Hospital
mi
from
Hartford, CT
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
Christiana Care Health Services, Inc
mi
from
Newark, DE
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
Christiana Care Health Services, Inc
mi
from
Newark, DE
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
Northside Hospital
mi
from
Atlanta, GA
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
Northside Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
St. Joseph's/Candler Health System
mi
from
Savannah, GA
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
St. Joseph's/Candler Health System
mi
from
Savannah, GA
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
Our Lady of the Lake/ Mary Bird Perkins
mi
from
Baton Rouge, LA
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
Our Lady of the Lake/ Mary Bird Perkins
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
The Cancer Institute Catholic Health Initiatives
mi
from
Towson, MD
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
The Cancer Institute Catholic Health Initiatives
mi
from
Towson, MD
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
Billings Clinical Cancer Center
mi
from
Billings, MT
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
Billings Clinical Cancer Center
mi
from
Billings, MT
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
CHI, St. Fancis
mi
from
Grand Island, NE
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
CHI, St. Fancis
mi
from
Grand Island, NE
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
CHI, Good Samaritan
mi
from
Kearney, NE
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
CHI, Good Samaritan
mi
from
Kearney, NE
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
Lehigh Valley Hospital
mi
from
Allentown, PA
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
Lehigh Valley Hospital
mi
from
Allentown, PA
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
Spartanburg Regional Hospital
mi
from
Spartanburg, SC
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
Spartanburg Regional Hospital
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
Sanford Health
mi
from
Sioux Falls, SD
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
Sanford Health
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated:  12/31/1969
Ascension Health Systems
mi
from
Milwaukee, WI
Cancer Symptom Data From Multiple Treatment Centers
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Status: Enrolling
Updated: 12/31/1969
Ascension Health Systems
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA
Phase I/II Study of Intravenous Ascorbic Acid in Combination With Irinotecan Versus Irinotecan Alone for Advanced Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA
Phase I/II Study of Intravenous Ascorbic Acid in Combination With Irinotecan Versus Irinotecan Alone for Advanced Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials